OSCAR PAKIER: Open Payments
NPI 1447320304 · TARZANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,592 in 30 payments from 8 companies in 2025. Trend: 2023 $2,561 · 2024 $2,780 · 2025 $1,592
Food & beverage: $1,588Education: $4
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $442 |
| ABBVIE INC. | 6 | $246 |
| Axsome Therapeutics, Inc. | 2 | $244 |
| Otsuka America Pharmaceutical, Inc. | 6 | $219 |
| E.R. Squibb & Sons, L.L.C. | 3 | $153 |
| Alkermes, Inc. | 5 | $147 |
| Supernus Pharmaceuticals, Inc. | 1 | $124 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $18 |
Products named: CAPLYTA, VRAYLAR, Auvelity, REXULTI, COBENFY, Qelbree, LYBALVI, ARISTADA.
Industry payments across CA — which companies pay providers there.
